Cite
68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC).
MLA
Valle, J. W., et al. “68O Impact of Mutation Status on Efficacy Outcomes in TOPAZ-1: A Phase III Study of Durvalumab (D) or Placebo (PBO) plus Gemcitabine and Cisplatin (+GC) in Advanced Biliary Tract Cancer (BTC).” Annals of Oncology, vol. 33, Nov. 2022, p. S1457. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.10.104.
APA
Valle, J. W., Qin, S., Antonuzzo, L., Tougeron, D., Lee, C.-K., Tan, B. J., Ikeda, M., Guthrie, V., McCoon, P., Lee, Y. S., Rokutanda, N., Żotkiewicz, M., Cohen, G., & Oh, D.-Y. (2022). 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). Annals of Oncology, 33, S1457. https://doi.org/10.1016/j.annonc.2022.10.104
Chicago
Valle, J.W., S. Qin, L. Antonuzzo, D. Tougeron, C-K. Lee, B.J. Tan, M. Ikeda, et al. 2022. “68O Impact of Mutation Status on Efficacy Outcomes in TOPAZ-1: A Phase III Study of Durvalumab (D) or Placebo (PBO) plus Gemcitabine and Cisplatin (+GC) in Advanced Biliary Tract Cancer (BTC).” Annals of Oncology 33 (November): S1457. doi:10.1016/j.annonc.2022.10.104.